Shen Nannan, Li Xiaoguang, Zhou Tong, Bilal Muhammad U, Du Ning, Hu Yingying, Qin Wei, Xie Yingming, Wang Hongtao, Wu Jianwei, Ju Jiaming, Fang Zhiwei, Wang Lihong, Zhang Yong
Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin 150081, China.
Department of Endocrinology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
J Ethnopharmacol. 2014 Nov 18;157:161-70. doi: 10.1016/j.jep.2014.09.035. Epub 2014 Oct 3.
Shensong Yangxin Capsule (SSYX), a traditional Chinese herbal medicine, has long been used clinically to treat arrhythmias in China. However, the effect of SSYX on interstitial fibrosis in diabetic cardiomyopathy is unknown. The objective of this study was to investigate the effects of SSYX on myocardial fibrosis in diabetic rats.
The antifibrotic effect of SSYX was investigated in streptozocin (STZ)-induced diabetic rats with high fat-diet (HFD). Fasting blood glucose, heart weight/body weight (HW/BW) ratio, total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were measured. Echocardiography and histology examination were carried out to evaluate heart function. Expressions of Smad7, TGF-β1, collagen I (col-1), collagen III (col-3), MMP-2, MMP-9 and α-SMA mRNA in heart tissues were measured by real time polymerase chain reaction (PCR). TGF-β1, Smad2/3, p-Smad2/3 and Smad7 protein levels were measured by western blot analysis. Proliferation of cardiac fibroblast was detected via immunofluorescence.
SSYX markedly decreased HW/BW ratio and improved the impaired cardiac function of type-2 diabetes mellitus (T2DM) rats. Transmission electron microscopy (TEM), haematoxylin and eosin (HE) and Masson staining results showed that SSYX attenuated cardiac fibrosis and collagen deposition in T2DM rats. Moreover, mRNA levels of TGF-β1, col-1, col-3, MMP-2, MMP-9 and α-SMA were downregulated, whereas Smad7 expression was upregulated after treatment with SSYX in rats with cardiac fibrosis. Furthermore, SSYX decreased protein levels of TGF-β1 and p-Smad2/3, and increased Smad7 expression.
TGF-β1/Smad signaling is involved in the cardiac fibrosis in diabetic cardiomyopathy and SSYX inhibits fibrosis and improves cardiac function via suppressing this pathway. Therefore, SSYX might be considered as an alternative therapeutic remedy for diabetic cardiomyopathy.
参松养心胶囊(SSYX)是一种传统中药,在中国长期用于临床治疗心律失常。然而,SSYX对糖尿病性心肌病间质纤维化的作用尚不清楚。本研究的目的是探讨SSYX对糖尿病大鼠心肌纤维化的影响。
在链脲佐菌素(STZ)诱导的高脂饮食(HFD)糖尿病大鼠中研究SSYX的抗纤维化作用。测量空腹血糖、心脏重量/体重(HW/BW)比值、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)。进行超声心动图和组织学检查以评估心脏功能。通过实时聚合酶链反应(PCR)测量心脏组织中Smad7、TGF-β1、I型胶原(col-1)、III型胶原(col-3)、MMP-2、MMP-9和α-SMA mRNA的表达。通过蛋白质印迹分析测量TGF-β1、Smad2/3、p-Smad2/3和Smad7蛋白水平。通过免疫荧光检测心脏成纤维细胞的增殖。
SSYX显著降低HW/BW比值,改善2型糖尿病(T2DM)大鼠受损的心脏功能。透射电子显微镜(TEM)、苏木精和伊红(HE)以及Masson染色结果表明,SSYX减轻了T2DM大鼠的心脏纤维化和胶原沉积。此外,在心脏纤维化大鼠中,用SSYX治疗后,TGF-β1、col-1、col-3、MMP-2、MMP-9和α-SMA的mRNA水平下调,而Smad7表达上调。此外,SSYX降低了TGF-β1和p-Smad2/3的蛋白水平,并增加了Smad7的表达。
TGF-β1/Smad信号通路参与糖尿病性心肌病中的心脏纤维化,SSYX通过抑制该通路抑制纤维化并改善心脏功能。因此,SSYX可能被认为是糖尿病性心肌病的一种替代治疗药物。